Industry News

Pharmaceutical Industry News

In challenging IRA price…

August 18th, 2026|Fierce Pharma|

In challenging IRA price negotiations, Teva Pharmaceuticals has gained a partial win as the U.S. Court of Appeals for Washington, D.C., sent a previous ruling back to a lower court for further review. The challenge

Fierce editors break down Big…

August 18th, 2026|Fierce Pharma|

Fierce editors break down Big Pharma’s second-quarter results, from AI and new leadership to the oral GLP-1 race and potential new blockbusters.

Biokin Pharma’s iza-bren, a…

August 18th, 2026|Fierce Pharma|

Biokin Pharma’s iza-bren, a first-in-class antibody-drug conjugate partnered with Bristol Myers Squibb, has posted another positive phase 3 readout.

After a year of impairments,…

August 18th, 2026|Fierce Pharma|

After a year of impairments, revenue downgrades and the ousting of its chief executive officer, Australian plasma and vaccine specialist CSL has flashed signs of recovery, projecting mid-single-digit growth in fiscal year 2027 for its

Revance has appointed Ulta Beauty…

August 18th, 2026|Fierce Pharma|

Revance has appointed Ulta Beauty and Procter & Gamble alum Janelle Wichmann as its new chief marketing officer for skincare as it looks to boost commercial penetration of its Botox rival, Daxxify.

Regeneron’s Pasatru has crossed…

August 18th, 2026|Fierce Pharma|

Regeneron's Pasatru has crossed the finish line with FDA approval after more than ten years of development. The drug is only the second approved treatment for FOP, an ultra-rare genetic condition that causes patients' soft

After investors blanched last…

August 18th, 2026|Fierce Pharma|

After investors blanched last month at a slower-than-expected launch timeline for Celcuity’s novel breast cancer med Revtorpyk, the company used much of its latest earnings call to address concerns over—and reaffirm confidence in—the pace of

The phase 3 misstep could undercut…

August 17th, 2026|Fierce Pharma|

The phase 3 misstep could undercut EyePoint’s ambition to displace Eylea as the high-value treatment of choice for wAMD, a leading cause of blindness in adults over 50, while putting significant pressure on the identical

Quanovate voluntarily agreed to…

August 17th, 2026|Fierce Pharma|

Quanovate voluntarily agreed to discontinue the marketing claims on its Mira fertility monitor and test wands that competitor Procter & Gamble had challenged before the BBB National Programs’ National Advertising Division.

In the first major workforce…

August 17th, 2026|Fierce Pharma|

In the first major workforce reduction disclosed under new CEO Belén Garijo, Sanofi is laying off 229 employees from legacy Blueprint Medicines in Massachusetts as part of a post-acquisition integration.

Sandoz has collaborated with…

August 17th, 2026|Fierce Pharma|

Sandoz has collaborated with Shanghai Henlius to gain commercialization rights to three biosimilars that are in early development. The deal is for Sandoz to pay up to $100.5 million up front for the initial assets

AstraZeneca reported phase 3 lung…

August 17th, 2026|Fierce Pharma|

AstraZeneca reported phase 3 lung cancer wins for Enhertu and a combination of Orpathys and Tagrisso, but the victories were eclipsed by the failure of its PD-1/CTLA-4 bispecific antibody in a simultaneous readout.

The pharmaceutical industry…

August 17th, 2026|Fierce Pharma|

The pharmaceutical industry creates some of the most valuable products in human history: Medicines that can extend, save and better our lives. The product is rarely up for question, but the industry itself can struggle